

R&D, Administration and Europe Office
Cisbio Bioassays
Phone: +33 (0)4 66 79 67 05
Fax: +33 (0)4 66 79 19 20
E-mail: bioassays@cisbio.com

Japan Office
Sceti Medical Labo K.K.
Phone: +81 (0)3 5510 2932
Fax: +81 (0)3 5510 0130
E-mail: reagent@scetimedilabo.co.jp

USA Office
Cisbio US, Inc.
Phone : 888 963 4567
Fax : 781 687 1500
E-mail : htrfinfo@cisbio.us

www.htrf.com

Cell line Information

For in vitro research use only
Version Feb1A




Tag-Lite® AT1 stable cell line

Cell line code	C1SU1AT1
Storage	Liquid nitrogen
Batch	04 feb 2010
Passages number	6
Total cells	8 millions/vial

Target information

Target:	Angiotensin AT1 receptor This receptor is fused in N-term position with SNAP-tag.
Species:	Human
NCBI accession number:	NM_000685.4



Cell culture information

Cellular background:	HEK293 Adherent
Culture medium:	DMEM (4.5g/l Glucose)10%FCS+4mM L-Glutamine+0.6µg/ml G418
Growth conditions:	37°C, 5%CO2
Freezing medium:	90% FCS+10%DMSO

Thawing procedure:

Thaw the vials of cryopreserved cells rapidly in a water bath at 37°C. Carefully transfer the cells in a cell culture vessel containing the appropriate volume of pre-warmed culture medium without G418 so that cell density reaches $4 \cdot 10^4$ to $8 \cdot 10^4$ cells/cm². The day after, ensure that cells have properly attached and carefully replace with fresh culture medium supplemented with G418. Allow cells for growth until 80% confluency then transfer in a new cell culture vessel.

Subculturing:

Once cells have reached 80% confluency, carefully remove and discard culture medium. Rinse once with PBS then add the appropriate volume of cell dissociation solution. Observe under microscope until cell layer is detached. Add growth medium, then centrifuge 3min at 180g. Replace supernatant by fresh cell culture medium and pipet up and down to remove aggregates. Count cells, and split in a new culture vessel with a ratio 1:5 maximum. Replace medium once or twice a week.

Biosafety and compliance

Biosafety level: 1

Warning:

This product contains material of biologic origin. Use for research purposes only. Do not use in humans or for diagnostic purposes. The purchaser assumes risk and responsibility concerning reception, handling and storage. The use of the cell line will be done in appropriate safety and handling precautions to minimize health and environmental impact. The product is genetically modified and must be used according to biosafety level S1. The purchaser declares the authorization to manipulate GMO and agrees to apply guidelines, laws and regulations.

Tag-lite stable cell line validation

Tag-lite cell line is a comprehensive cellular platform certified for:

Ligand binding assay
Receptor dimerization assays
IP-One assay
Phospho-ERK assay
Internalization assay

For each application a protocol can be downloaded on www.htrf.com

Copyright © 2010 CIS bio international, France

HTRF®, Tag-lite®, and the HTRF® logo are trademarks belonging to CIS bio international.

HTRF® products are manufactured under one or more of the following patents and foreign equivalent : EP 0 180 492 / US 4,927,923 / US 5,220,012 / US 5,432,101 – EP 0 321 353 / US 5,457,185 / US 5,534,622 / US 5,346,996 / US 5,162,508 – EP 0 539 477 / US 5,512,493 – EP 0 539 435 / US 5,627,074 – EP 0 569 496 / US 5,527,684. CIS bio international hereby grants to those buying HTRF® products from CIS bio international or its affiliates / distributors, a worldwide, non-exclusive, royalty-free, limited license to use HTRF® technology with said products for in-house life science research only. Signal amplification and correction using HTRF® technology are covered by the following U.S. patents or patent applications and foreign equivalents : US 5,512,493 – US 5,527,684 – US 6,352,672.

SNAP-tag and CLIP-tag are trademarks exclusively licensed to New England Biolabs. Plasmids encoding SNAP-tag and CLIP-tag and their substrates are made under license from New England Biolabs and may be covered by one or more of the following published patent applications filed internationally in US, EP and JP and also in additional jurisdictions : WO2002/083937 WO2004/031405 WO2004/104588 WO2004/031404 WO2005/085470 WO2008/012296 US, WO2008/122604 and EP patents 1410023 and 1696234.